<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04012320</url>
  </required_header>
  <id_info>
    <org_study_id>Local/2018/TAT-01</org_study_id>
    <nct_id>NCT04012320</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety on the Use of Bisphosphonates in Paediatrics</brief_title>
  <acronym>Bisphosphonate</acronym>
  <official_title>Efficacy and Safety on the Use of Bisphosphonates in Paediatrics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators suppose that the impact of bisphosphonate therapy is beneficial on the bone
      during the growth period with few adverse events.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 31, 2018</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>fracture rates</measure>
    <time_frame>2 years</time_frame>
    <description>(numbers)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>bone mineral density</measure>
    <time_frame>2 years</time_frame>
    <description>(Z-score)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pain frequency</measure>
    <time_frame>2 years</time_frame>
    <description>(never, occasional, regular)</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">99</enrollment>
  <condition>Bone Fragile</condition>
  <condition>Bisphosphonate-Associated Osteonecrosis</condition>
  <condition>Children</condition>
  <condition>Adverse Events</condition>
  <arm_group>
    <arm_group_label>Pamidronate therapy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Zoledronate therapy</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention, observational study</intervention_name>
    <description>No intervention, observational study</description>
    <arm_group_label>Pamidronate therapy</arm_group_label>
    <arm_group_label>Zoledronate therapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients under 18 years old who started intravenous bisphosphonates for primary or
        secondary osteoporosis in paediatric departments of Montpellier and Nimes University
        Hospitals between January 2012 and August 2018 were included.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  be under 18 years of age

          -  have been treated by intravenous bisphosphonates for primary or secondary osteoporosis

        Exclusion Criteria:

          -  be over 18 years of age
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHUNimes</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 14, 2019</study_first_submitted>
  <study_first_submitted_qc>July 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2019</study_first_posted>
  <last_update_submitted>July 8, 2019</last_update_submitted>
  <last_update_submitted_qc>July 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteonecrosis</mesh_term>
    <mesh_term>Bisphosphonate-Associated Osteonecrosis of the Jaw</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

